SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Sepsis/Acute Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject10/21/2003 4:09:53 AM
From: nigel bates  Read Replies (1) of 89
 
Xenova (& Genetech, Celltech) / OX40 / influenza
Message 19419567
...David Oxlade, Chief Executive of Xenova, said, 'We are very encouraged by these novel findings from the work conducted by Imperial College on our OX40 platform technology. The demonstration in pre-clinical studies that down-regulation of the immune response by blocking the OX40-OX40 ligand interaction alleviates the symptoms of influenza, without affecting the ability to clear the virus, is very exciting. This new research suggests that the down-regulation of OX40 signaling could play an important role in the fight against the symptoms of influenza and perhaps other diseases similarly characterised by excessive immune response'...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News